Lupin Inc. Submits ANDA for Revefenacin to FDA
Lupin Inc. has submitted an Abbreviated New Drug Application (ANDA) for Revefenacin, currently under standard review.
Asset / Drug
Drug and asset intelligence for Revefenacin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.